An Open-label Extension of SPG302-ALS-001 Study to Evaluate the Long-term Safety and Efficacy of Daily Oral SPG302 Treatment in Participants With Amyotrophic Lateral Sclerosis
Latest Information Update: 04 Jul 2025
At a glance
- Drugs SPG 302 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Spinogenix
Most Recent Events
- 27 Jun 2025 Status changed from not yet recruiting to recruiting.
- 14 May 2025 Planned initiation date changed from 29 Apr 2025 to 29 May 2025.
- 02 Apr 2025 New trial record